Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg ‐positive donors to HBsAg ‐negative recipients
Liver International · 2023-11 · 43 (11) · 2415-2424
DOI: 10.1111/liv.15703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 17.08.2023. Verfasst von Saifu Yin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Kidney Transplantation, Liver Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background & Aims HBsAg‐positive (HBsAg[+]) donors are rarely accepted for kidney transplantation (KT), especially when the donor is also HBV DNA‐positive (HBV DNA[+]) or HBeAg‐positive (HBeAg[+]) serologically. This study aimed to report kidney transplant outcomes from HBsAg(+) donors to HBsAg(−) recipients.
Methods
Consecutive cases were retrospectively identified from 1 July 2017 to 31 December 2020. KTs from HBsAg(−)/HBcAb‐positive (HBcAb[+]) donors to HBcAb(−) recipients were selected as the control group. The primary outcomes were de novo HBV infection (DNH), graft and patient survival.
Results
We identified 105 HBsAg(−) recipients who received HBsAg(+) kidneys and 516 HBcAb(−) recipients who received HBcAb(+) kidneys. A higher DNH rate was observed after receiving HBsAg(+) kidneys than after receiving HBcAb(+) kidneys after a median follow‐up of 23.0 months (4/105[3.8%] vs. 2/516[0.4%], p = .009). All four infected recipients receiving HBsAg(+) kidneys had HBsAg clearance after treatment. Graft and patient survival were comparable between the groups ( p = .630, p = .910). The DNH rates were 0/22(0%), 3/70(4.3%) and 1/13(7.7%) after receiving HBsAg(+), HBV DNA(+) and HBeAg(+) kidneys, respectively ( p = .455). The DNH rate was lower if the donor had received antiviral treatment (4/42[9.5%] vs. 0/63[0%], p = .023). HBsAb(−) recipients had a higher DNH incidence than HBsAb(+) recipients (3/25[12.0%] vs. 1/80[1.3%], p = .041).
Conclusions
The use of HBsAg(+) donors contributed to comparable graft and patient survival, but HBV DNA(+) or HBeAg(+) donors and HBsAb(−) recipients maybe associated with a higher risk of HBV infection. These findings help expand the donor pool and emphasize the role of donor antiviral treatment and recipient HBV immunity in establishing optimal prophylactic regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
- Kidney Transplantation Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Saifu Yin
Zitieren
APA
Yin, S., Wu, L., Zhang, F., Huang, X., Wu, J., Wang, X., & Lin, T. (2023). Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg ‐positive donors to HBsAg ‐negative recipients. Liver International, 43(11), 2415-2424. https://doi.org/10.1111/liv.15703
Vancouver
Yin S, Wu L, Zhang F, Huang X, Wu J, Wang X, et al. Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg ‐positive donors to HBsAg ‐negative recipients. Liver International. 2023;43(11):2415-2424. doi:10.1111/liv.15703
BibTeX
@article{Yin2023,
author = {Yin, Saifu and Wu, Lijuan and Zhang, Fan and Huang, Xinyi and Wu, Jiapei and Wang, Xianding and Lin, Tao},
title = {Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg ‐positive donors to HBsAg ‐negative recipients},
journal = {Liver International},
year = {2023},
volume = {43},
number = {11},
pages = {2415--2424},
doi = {10.1111/liv.15703}
}
EUVIMED